Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 15, 2016British Journal of HaematologyOpen Access

Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies

View Full Paper
Ask AI
Bookmark
Share

Authors

TPThomas PrébetJDJacques DelaunayEWEric Wattel

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Prébet et al. (2016) studied this question.

synapsesocial.com/papers/6a9ed70de2d0fc9581be7982https://doi.org/10.1111/bjh.14427
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure2011 · 485 citations
  2. 2A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium2008 · 40 citations
  3. 3Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E19052014 · 247 citations
  4. 4Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings2017 · 17 citations